BioSpace News Archive

Foresite Raises $900M in Sixth Fund to Invest in Life Science Startups

Among the biggest raises this year, Foresite Capital’s $900 million fund will support biotech companies working in precision medicine and life science infrastructure.

June 13, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Moderna’s Next-Gen COVID Vaccine Beats Current Shot in Pivotal Adult Efficacy Trial

Moderna said Thursday it plans to talk to regulators about the next steps after showing its next-generation candidate is more efficacious in adults than the biotech’s existing Spikevax COVID-19 shot.

June 13, 2024
·
2 min read
·
Nick Paul Taylor
Policy

Opinion: Regulatory Flexibility Can Accelerate Rare Disease Drug Development

Shifts in the FDA’s approach present an unprecedented opportunity to solve problems with patient access and trial design.

June 13, 2024
·
6 min read
Drug Development

Pfizer’s Gene Therapy for Duchenne Muscular Dystrophy Fails Phase III Trial

Pfizer’s investigational Duchenne muscular dystrophy gene therapy, fordadistrogene movaparvovec, failed in a late-stage study to significantly improve motor function in patients versus placebo.

June 13, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Secondary Cancer Risk Is Low After CAR T Cell Treatment: Stanford Study

Results of a large Stanford Medicine study, published Wednesday in The New England Journal of Medicine, finds CAR-T therapies carry a low risk of secondary malignancies not related to the T cells.

June 13, 2024
·
2 min read
·
Tristan Manalac
Business

Santa Ana Bio Launches With $168M, Targets Autoimmune and Inflammatory Diseases

With Versant Ventures as a founding investor, Santa Ana Bio emerged from stealth Thursday with $168 million in combined Series A and B funding to support plans to have two programs in the clinic by next year.

June 13, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Coherus, Junshi’s PD-1 Blocker Loqtorzi Aces Phase III Liver Cancer Trial

Coherus BioSciences and Junshi Biosciences’ PD-1 inhibitor Loqtorzi significantly boosted progression-free and overall survival in a late-stage study of patients with advanced hepatocellular carcinoma.

June 13, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Aldeyra Therapeutics, Inc. announced the completion of enrollment in a Phase 3 dry eye chamber clinical trial of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease.

June 13, 2024
·
8 min read
Drug Development

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

Moderna, Inc. announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary efficacy endpoint, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax.

June 13, 2024
·
4 min read
Drug Development

Opus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs

Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, announced it has received $1.7 million in project-based funding from the Foundation Fighting Blindness to help advance two preclinical candidate programs.

June 13, 2024
·
3 min read